宰天明, 刘林栋, 王培炎, 赵傲. 磁共振成像用于前列腺癌的筛查价值[J]. 中国辐射卫生, 2023, 32(5): 560-564.
ZAI Tianming, LIU Lindong, WANG Peiyan, ZHAO Ao. Value of magnetic resonance imaging in screening for prostate cancer. Chinese Journal of Radiological Health, 2023, 32(5): 560-564.
[1] Rebello RJ, Oing C, Knudsen KE, et al. Prostate cancer[J]. Nat Rev Dis Primers, 2021, 7(1): 9. DOI: 10.1038/s41572-020-00243-0 [2] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660 [3] Cai QL, Chen YG, Zhang DR, et al. Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030[J]. Transl Androl Urol, 2020, 9(2): 196-209. DOI: 10.21037/tau.2020.02.21 [4] Teoh JYC, Hirai HW, Ho JMW, et al. Global incidence of prostate cancer in developing and developed countries with changing age structures[J]. PLoS One, 2019, 14(10): e0221775. DOI: 10.1371/journal.pone.0221775 [5] Rawla P. Epidemiology of prostate cancer[J]. World J Oncol, 2019, 10(2): 63-89. DOI: 10.14740/wjon1191 [6] Alvarez CS, Virani S, Meza R, et al. Current and future burden of prostate cancer in Songkhla, Thailand: analysis of incidence and mortality trends from 1990 to 2030[J]. J Glob Oncol, 2018, 4: 1-11. DOI: 10.1200/JGO.17.00128 [7] Ye DW, Zhu Y. Prostate cancer and prostatic diseases best of China, 2018[J]. Prostate Cancer Prostatic Dis, 2019, 22(1): 1-2. DOI: 10.1038/s41391-018-0117-y [8] 李星, 曾晓勇. 中国前列腺癌流行病学研究进展[J]. 肿瘤防治研究,2021,48(1):98-102. DOI: 10.3971/j.issn.1000-8578.2021.20.0370 Li X, Zeng XY. Advances in epidemiology of prostate cancer in China[J]. Cancer Res Prev Treat, 2021, 48(1): 98-102. DOI: 10.3971/j.issn.1000-8578.2021.20.0370 [9] Yamada Y, Beltran H. Clinical and biological features of neuroendocrine prostate cancer[J]. Curr Oncol Rep, 2021, 23(2): 15. DOI: 10.1007/s11912-020-01003-9 [10] Yu W, Zhou LQ. Early diagnosis of prostate cancer from the perspective of Chinese physicians[J]. J Cancer, 2020, 11(11): 3264-3273. DOI: 10.7150/jca.36697 [11] Barry MJ, Simmons LH. Prevention of prostate cancer morbidity and mortality: primary prevention and early detection[J]. Med Clin North Am, 2017, 101(4): 787-806. DOI: 10.1016/j.mcna.2017.03.009 [12] Wilt TJ, Dahm P. PSA screening for prostate cancer: why saying no is a high-value health care choice[J]. J Natl Compr Canc Netw, 2015, 13(12): 1566-1574. DOI: 10.6004/jnccn.2015.0182 [13] Ilic D, Djulbegovic M, Jung JH, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis[J]. BMJ, 2018, 362: k3519. DOI: 10.1136/bmj.k3519 [14] Bagguley D, Ong S, Buteau JP, et al. Role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer[J]. Future Oncol, 2021, 17(17): 2225-2241. DOI: 10.2217/fon-2020-1293 [15] 夏标, 吴海璐, 张天富,等. 多参数磁共振成像在前列腺癌中的应用进展[J]. 国际放射医学核医学杂志,2022,46(1):58-63. DOI: 10.3760/cma.j.cn121381-202012025-00138 Xia B, Wu HL, Zhang TF, et al. Progress in the application of multiparameter magnetic resonance imaging in prostate cancer[J]. Int J Radiat Med Nucl Med, 2022, 46(1): 58-63. DOI: 10.3760/cma.j.cn121381-202012025-00138 [16] Giganti F, Moore CM. MRI in early detection of prostate cancer[J]. Curr Opin Urol, 2019, 29(6): 563-568. DOI: 10.1097/MOU.000000000000066810.1016/j.mcna.2020.08.007 [17] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)前列腺癌诊疗指南2020[M]. 北京: 人民卫生出版社, 2020: 1-20. Chinese Society of Clinical Oncology Guideline Working Committee.Chinese society of Clinical Oncology (CSCO) guidelines for the diagnosis and treatment of prostate cancer 2020[M].Beijing: People's Medical Publishing House, 2020: 1-20. [18] Sui YB, Li J, Zou ZX, et al. Comparison of diagnostic value of multi-slice spiral CT and MRI for different pathological stages of prostate cancer[J]. Oncol Lett, 2019, 17(6): 5505-5510. DOI: 10.3892/ol.2019.10272 [19] Zagars GK, Geara FB, Pollack A, et al. The T classification of clinically localized prostate cancer. An appraisal based on disease outcome after radiation therapy[J]. Cancer, 1994, 73(7): 1904-1912. DOI: 10.1002/1097-0142(19940401)73:7<1904::aid-cncr2820730722>3.0.co;2-6 [20] Lowrance W, Dreicer R, Jarrard DF, et al. Updates to advanced prostate cancer: AUA/SUO Guideline (2023)[J]. J Urol, 2023, 209(6): 1082-1090. DOI: 10.1097/JU.0000000000003452 [21] Wilt TJ, Scardino PT, Carlsson SV, et al. Prostate-specific antigen screening in prostate cancer: perspectives on the evidence[J]. J Natl Cancer Inst, 2014, 106(3): dju010. DOI: 10.1093/jnci/dju010 [22] Surasi DSS, Chapin B, Tang C, et al. Imaging and management of prostate cancer[J]. Semin Ultrasound CT MRI, 2020, 41(2): 207-221. DOI: 10.1053/j.sult.2020.02.001 [23] Alzain AF, Elhussein N, Fadulelmulla IA, et al. Common computed tomography artifact: source and avoidance[J]. Egypt J Radiol Nucl Med, 2021, 52(1): 151. DOI: 10.1186/s43055-021-00530-0 [24] Grover VPB, Tognarelli JM, Crossey MME, et al. Magnetic resonance imaging: principles and techniques: lessons for clinicians[J]. J Clin Exp Hepatol, 2015, 5(3): 246-255. DOI: 10.1016/j.jceh.2015.08.001 [25] 张龙敏, 刘爱连. 前列腺癌MRI诊断技术研究进展[J]. 国际放射医学核医学杂志,2014,38(1):53-58. DOI: 10.3760/cma.j.issn.1673-4114.2014.01.011 Zhang LM, Liu AL. Advances in MRI diagnosis of prostate cancer[J]. Int J Radiat Med Nucl Med, 2014, 38(1): 53-58. DOI: 10.3760/cma.j.issn.1673-4114.2014.01.011 [26] Wang YXJ, Huang H, Zheng CJ, et al. Diffusion-weighted MRI of the liver: challenges and some solutions for the quantification of apparent diffusion coefficient and intravoxel incoherent motion[J]. Am J Nucl Med Mol Imaging, 2021, 11(2): 107-142 [27] 邱婉莉. 高场强MRI诊断前列腺癌的临床价值研究[J]. 影像研究与医学应用,2023,7(12):170-172. DOI: 10.3969/j.issn.2096-3807.2023.12.056 Qiu WL. Application value of high-field MRI for diagnosis of prostate cancer[J]. J Imag Res Med Appl, 2023, 7(12): 170-172. DOI: 10.3969/j.issn.2096-3807.2023.12.056 [28] 孔凡武, 李健康, 闫玉玲. 多模态MRI参数检测在前列腺疾病中的应用价值[J]. 中国CT和MRI杂志,2023,21(5):99-101. DOI: 10.3969/j.issn.1672-5131.2023.05.034 Kong FW, Li JK, Yan YL. Application value of multimodal MRI parameters in prostate diseases[J]. Chin J CT MRI, 2023, 21(5): 99-101. DOI: 10.3969/j.issn.1672-5131.2023.05.034 [29] Martins M, Regusci S, Rohner S, et al. The diagnostic accuracy of multiparametric MRI for detection and localization of prostate cancer depends on the affected region[J]. BJUI Compass, 2021, 2(3): 178-187. DOI: 10.1002/bco2.62 [30] Nam R, Patel C, Milot L, et al. Prostate MRI versus PSA screening for prostate cancer detection (the MVP Study): a randomised clinical trial[J]. BMJ Open, 2022, 12(11): e059482. DOI: 10.1136/bmjopen-2021-059482
